The Supreme Court case that could slow generic drugs
Summary
This episode of An Arm and a Leg examines the Supreme Court case Hikma v. Amarin, which could delay access to affordable generic drugs. Host Dan Weissman and producer Emily Pizzacretta explain how "skinny labels" allow generics to launch before all patents expire, a practice now challenged by brand-name manufacturers claiming induced infringement. Legal experts warn that ruling against generics may deter competition, keeping drug prices high for patients like those served by Dr. Anmol Gupta.
Topics discussed
Sound Politics: Seattle Mayor Katie Wilson's early challenges
Introduction: High drug costs and the Supreme Court case
Hosts Dan Weissman and Emily Pizzacretta introduce the story
Explaining patents, generics, and the Hatch-Waxman Act
The concept of 'skinny labels' in generic drug marketing
The specific case: Vasepa, Amarin, and Hikma Pharmaceuticals
Amarin's claim of induced infringement by Hikma
Legal precedent: The GSK v. Teva ruling and its impact
Ad break: Booming podcast on Seattle's economy
Production credits and KFF Health News partnership
Stakes: Why the Supreme Court case matters for the industry
Potential delays in generic drug availability
Doctor's perspective on patient access to affordable meds
Outro, credits, and support information
Ad break: Seattle Eats podcast promotion
Listen ad-free on Castria